Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUBP9O)

• Drug Name: Voglibose Drug Info
• Synonyms: Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol
• Therapeutic Class: Hypoglycemic Agents
• Cross-matching ID:
  PubChem CID: 444020
  ChEBI ID: CHEMBL476960
  CAS Number: CAS 83480-29-9
  TTD Drug ID: D04ZTY

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Oxidative phosphorylation	2.08	9.09e-3	93/133 (69.92%)	ATP5F1C;COX7B;NDUFB2;...
Glycine, serine and threonine metabolism	2.01	4.55e-3	31/40 (77.5%)	GATM;GLDC;PGAM1;...
Glycolysis / Gluconeogenesis	1.88	2.43e-2	56/67 (83.58%)	PFKL;ADH5;PGAM1;...
Biosynthesis of unsaturated fatty acids	1.87	1.82e-2	21/27 (77.78%)	SCD;HACD3;ELOVL2;...
Amyotrophic lateral sclerosis	1.77	3.82e-2	267/364 (73.35%)	DAXX;TUBB2A;CYCS;...
Parkinson disease	1.77	3.64e-2	176/249 (70.68%)	DAXX;UCHL1;TUBB2A;...
Pentose phosphate pathway	1.74	4.42e-2	25/30 (83.33%)	PFKL;ALDOC;ALDOB;...
ECM-receptor interaction	-2.01	1.09e-2	80/88 (90.91%)	LAMB4;LAMA5;LAMC3;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼